Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jun;51(6):638–646. doi: 10.1136/thx.51.6.638

New prognostic factors in resectable non-small cell lung cancer.

E F Smit 1, H J Groen 1, T A Splinter 1, T Ebels 1, P E Postmus 1
PMCID: PMC1090499  PMID: 8693450

Full text

PDF
638

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baillie C. T., Winslet M. C., Bradley N. J. Tumour vasculature--a potential therapeutic target. Br J Cancer. 1995 Aug;72(2):257–267. doi: 10.1038/bjc.1995.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Buccheri G., Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994 Jul;7(7):1350–1364. doi: 10.1183/09031936.94.07071350. [DOI] [PubMed] [Google Scholar]
  3. Chang E. H., Furth M. E., Scolnick E. M., Lowy D. R. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature. 1982 Jun 10;297(5866):479–483. doi: 10.1038/297479a0. [DOI] [PubMed] [Google Scholar]
  4. Chang F., Syrjänen S., Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995 Apr;13(4):1009–1022. doi: 10.1200/JCO.1995.13.4.1009. [DOI] [PubMed] [Google Scholar]
  5. Chen Z. L., Perez S., Holmes E. C., Wang H. J., Coulson W. F., Wen D. R., Cochran A. J. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst. 1993 Mar 17;85(6):493–498. doi: 10.1093/jnci/85.6.493. [DOI] [PubMed] [Google Scholar]
  6. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995 Sep;147(3):545–560. [PMC free article] [PubMed] [Google Scholar]
  7. Crowley C. W., Cohen R. L., Lucas B. K., Liu G., Shuman M. A., Levinson A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021–5025. doi: 10.1073/pnas.90.11.5021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dameron K. M., Volpert O. V., Tainsky M. A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994 Sep 9;265(5178):1582–1584. doi: 10.1126/science.7521539. [DOI] [PubMed] [Google Scholar]
  9. Damjanov I. Lectin cytochemistry and histochemistry. Lab Invest. 1987 Jul;57(1):5–20. [PubMed] [Google Scholar]
  10. Dennis J. W., Laferté S., Waghorne C., Breitman M. L., Kerbel R. S. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 1987 May 1;236(4801):582–585. doi: 10.1126/science.2953071. [DOI] [PubMed] [Google Scholar]
  11. Ebina M., Steinberg S. M., Mulshine J. L., Linnoila R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 1;54(9):2496–2503. [PubMed] [Google Scholar]
  12. Feld R., Rubinstein L., Thomas P. A. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst. 1993 Feb 17;85(4):299–306. doi: 10.1093/jnci/85.4.299. [DOI] [PubMed] [Google Scholar]
  13. Fidler I. J., Ellis L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994 Oct 21;79(2):185–188. doi: 10.1016/0092-8674(94)90187-2. [DOI] [PubMed] [Google Scholar]
  14. Filderman A. E., Silvestri G. A., Gatsonis C., Luthringer D. J., Honig J., Flynn S. D. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis. 1992 Sep;146(3):707–710. doi: 10.1164/ajrccm/146.3.707. [DOI] [PubMed] [Google Scholar]
  15. Fisher D. E. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994 Aug 26;78(4):539–542. doi: 10.1016/0092-8674(94)90518-5. [DOI] [PubMed] [Google Scholar]
  16. Friend S. p53: a glimpse at the puppet behind the shadow play. Science. 1994 Jul 15;265(5170):334–335. doi: 10.1126/science.8023155. [DOI] [PubMed] [Google Scholar]
  17. Fujiwara T., Cai D. W., Georges R. N., Mukhopadhyay T., Grimm E. A., Roth J. A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994 Oct 5;86(19):1458–1462. doi: 10.1093/jnci/86.19.1458. [DOI] [PubMed] [Google Scholar]
  18. Georges R. N., Mukhopadhyay T., Zhang Y., Yen N., Roth J. A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993 Apr 15;53(8):1743–1746. [PubMed] [Google Scholar]
  19. Goss P. E., Baker M. A., Carver J. P., Dennis J. W. Inhibitors of carbohydrate processing: A new class of anticancer agents. Clin Cancer Res. 1995 Sep;1(9):935–944. [PubMed] [Google Scholar]
  20. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  21. Hall A. The cellular functions of small GTP-binding proteins. Science. 1990 Aug 10;249(4969):635–640. doi: 10.1126/science.2116664. [DOI] [PubMed] [Google Scholar]
  22. Harada M., Dosaka-Akita H., Miyamoto H., Kuzumaki N., Kawakami Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer. 1992 Jan 1;69(1):72–77. doi: 10.1002/1097-0142(19920101)69:1<72::aid-cncr2820690114>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  23. Harbeck N., Untch M., Pache L., Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer. 1994 Mar;69(3):566–571. doi: 10.1038/bjc.1994.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Harpole D. H., Jr, Herndon J. E., 2nd, Wolfe W. G., Iglehart J. D., Marks J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995 Jan 1;55(1):51–56. [PubMed] [Google Scholar]
  25. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  26. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., Suyama M., Takagi H., Nakamura Y., Takahashi T. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 1992 Mar;7(3):445–449. [PubMed] [Google Scholar]
  27. Holmes E. C., Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986 May;4(5):710–715. doi: 10.1200/JCO.1986.4.5.710. [DOI] [PubMed] [Google Scholar]
  28. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993 Jan 1;53(1):1–4. [PubMed] [Google Scholar]
  29. Isobe H., Miyamoto H., Shimizu T., Haneda H., Hashimoto M., Inoue K., Mizuno S., Kawakami Y. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer. 1990 Mar 15;65(6):1391–1395. doi: 10.1002/1097-0142(19900315)65:6<1391::aid-cncr2820650624>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  30. Kanters S. D., Lammers J. W., Voest E. E. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J. 1995 Aug;8(8):1389–1397. doi: 10.1183/09031936.95.08081389. [DOI] [PubMed] [Google Scholar]
  31. Kern J. A., Schwartz D. A., Nordberg J. E., Weiner D. B., Greene M. I., Torney L., Robinson R. A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990 Aug 15;50(16):5184–5187. [PubMed] [Google Scholar]
  32. Kern J. A., Slebos R. J., Top B., Rodenhuis S., Lager D., Robinson R. A., Weiner D., Schwartz D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 1994 Feb;93(2):516–520. doi: 10.1172/JCI117001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Lee J. S., Ro J. Y., Sahin A. A., Hong W. K., Brown B. W., Mountain C. F., Hittelman W. N. Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med. 1991 Apr 18;324(16):1084–1090. doi: 10.1056/NEJM199104183241603. [DOI] [PubMed] [Google Scholar]
  34. Levine A. J., Perry M. E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994 Mar;69(3):409–416. doi: 10.1038/bjc.1994.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Li Z. H., Zheng J., Weiss L. M., Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol. 1994 Feb;144(2):303–309. [PMC free article] [PubMed] [Google Scholar]
  36. Lindemann F., Schlimok G., Dirschedl P., Witte J., Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992 Sep 19;340(8821):685–689. doi: 10.1016/0140-6736(92)92230-d. [DOI] [PubMed] [Google Scholar]
  37. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  38. Macchiarini P., Fontanini G., Hardin M. J., Squartini F., Angeletti C. A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992 Jul 18;340(8812):145–146. doi: 10.1016/0140-6736(92)93217-b. [DOI] [PubMed] [Google Scholar]
  39. Martini N., Burt M. E., Bains M. S., McCormack P. M., Rusch V. W., Ginsberg R. J. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg. 1992 Sep;54(3):460–466. doi: 10.1016/0003-4975(92)90435-7. [DOI] [PubMed] [Google Scholar]
  40. Melhem M. F., Law J. C., el-Ashmawy L., Johnson J. T., Landreneau R. J., Srivastava S., Whiteside T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol. 1995 May;146(5):1170–1177. [PMC free article] [PubMed] [Google Scholar]
  41. Mills N. E., Fishman C. L., Rom W. N., Dubin N., Jacobson D. R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995 Apr 1;55(7):1444–1447. [PubMed] [Google Scholar]
  42. Mitsudomi T., Steinberg S. M., Oie H. K., Mulshine J. L., Phelps R., Viallet J., Pass H., Minna J. D., Gazdar A. F. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991 Sep 15;51(18):4999–5002. [PubMed] [Google Scholar]
  43. Miyake M., Hakomori S. I. A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. Biochemistry. 1991 Apr 2;30(13):3328–3334. doi: 10.1021/bi00227a023. [DOI] [PubMed] [Google Scholar]
  44. Miyake M., Taki T., Hitomi S., Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med. 1992 Jul 2;327(1):14–18. doi: 10.1056/NEJM199207023270103. [DOI] [PubMed] [Google Scholar]
  45. Miyamoto H., Harada M., Isobe H., Akita H. D., Haneda H., Yamaguchi E., Kuzumaki N., Kawakami Y. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res. 1991 Dec 1;51(23 Pt 1):6346–6350. [PubMed] [Google Scholar]
  46. Mountain C. F., Lukeman J. M., Hammar S. P., Chamberlain D. W., Coulson W. F., Page D. L., Victor T. A., Weiland L. H. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol. 1987 Jul;35(3):147–156. doi: 10.1002/jso.2930350302. [DOI] [PubMed] [Google Scholar]
  47. Niiranen A., Niitamo-Korhonen S., Kouri M., Assendelft A., Mattson K., Pyrhönen S. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol. 1992 Dec;10(12):1927–1932. doi: 10.1200/JCO.1992.10.12.1927. [DOI] [PubMed] [Google Scholar]
  48. Ogawa J., Tsurumi T., Inoue H., Shohtsu A. Relationship between tumor DNA ploidy and regional lymph node changes in lung cancer. Cancer. 1992 Apr 1;69(7):1688–1695. doi: 10.1002/1097-0142(19920401)69:7<1688::aid-cncr2820690708>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  49. Olson K. A., Fett J. W., French T. C., Key M. E., Vallee B. L. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):442–446. doi: 10.1073/pnas.92.2.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pairolero P. C., Williams D. E., Bergstralh E. J., Piehler J. M., Bernatz P. E., Payne W. S. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984 Oct;38(4):331–338. doi: 10.1016/s0003-4975(10)62281-3. [DOI] [PubMed] [Google Scholar]
  51. Pantel K., Izbicki J. R., Angstwurm M., Braun S., Passlick B., Karg O., Thetter O., Riethmüller G. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 1993 Mar 1;53(5):1027–1031. [PubMed] [Google Scholar]
  52. Passlick B., Izbicki J. R., Kubuschok B., Nathrath W., Thetter O., Pichlmeier U., Schweiberer L., Riethmüller G., Pantel K. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol. 1994 Sep;12(9):1827–1832. doi: 10.1200/JCO.1994.12.9.1827. [DOI] [PubMed] [Google Scholar]
  53. Passlick B., Izbicki J. R., Riethmüller G., Pantel K. p53 in non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 18;86(10):801–803. doi: 10.1093/jnci/86.10.801. [DOI] [PubMed] [Google Scholar]
  54. Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunnill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993 Sep 2;329(10):690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  55. Prives C. How loops, beta sheets, and alpha helices help us to understand p53. Cell. 1994 Aug 26;78(4):543–546. doi: 10.1016/0092-8674(94)90519-3. [DOI] [PubMed] [Google Scholar]
  56. Quinlan D. C., Davidson A. G., Summers C. L., Warden H. E., Doshi H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992 Sep 1;52(17):4828–4831. [PubMed] [Google Scholar]
  57. Read R. C., Schaefer R., North N., Walls R. Diameter, cell type, and survival in stage I primary non-small-cell lung cancer. Arch Surg. 1988 Apr;123(4):446–449. doi: 10.1001/archsurg.1988.01400280052010. [DOI] [PubMed] [Google Scholar]
  58. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
  59. Rosell R., Li S., Skacel Z., Mate J. L., Maestre J., Canela M., Tolosa E., Armengol P., Barnadas A., Ariza A. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 1993 Sep;8(9):2407–2412. [PubMed] [Google Scholar]
  60. Schneider P. M., Hung M. C., Chiocca S. M., Manning J., Zhao X. Y., Fang K., Roth J. A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 1989 Sep 15;49(18):4968–4971. [PubMed] [Google Scholar]
  61. Scott P. A., Harris A. L. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev. 1994 Oct;20(4):393–412. doi: 10.1016/0305-7372(94)90020-5. [DOI] [PubMed] [Google Scholar]
  62. Sklar M. D. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res. 1988 Feb 15;48(4):793–797. [PubMed] [Google Scholar]
  63. Slebos R. J., Kibbelaar R. E., Dalesio O., Kooistra A., Stam J., Meijer C. J., Wagenaar S. S., Vanderschueren R. G., van Zandwijk N., Mooi W. J. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990 Aug 30;323(9):561–565. doi: 10.1056/NEJM199008303230902. [DOI] [PubMed] [Google Scholar]
  64. Slebos R. J., Lee M. H., Plunkett B. S., Kessis T. D., Williams B. O., Jacks T., Hedrick L., Kastan M. B., Cho K. R. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320–5324. doi: 10.1073/pnas.91.12.5320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C. T., Pastorino U., Della Porta G., Pierotti M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992 Nov 1;52(21):6079–6082. [PubMed] [Google Scholar]
  66. Sozzi G., Miozzo M., Pastorino U., Pilotti S., Donghi R., Giarola M., De Gregorio L., Manenti G., Radice P., Minoletti F. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 1995 Jan 1;55(1):135–140. [PubMed] [Google Scholar]
  67. Strauss G. M., Kwiatkowski D. J., Harpole D. H., Lynch T. J., Skarin A. T., Sugarbaker D. J. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol. 1995 May;13(5):1265–1279. doi: 10.1200/JCO.1995.13.5.1265. [DOI] [PubMed] [Google Scholar]
  68. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992 May 15;52(10):2903–2906. [PubMed] [Google Scholar]
  69. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 1991;27(11):1372–1375. doi: 10.1016/0277-5379(91)90012-3. [DOI] [PubMed] [Google Scholar]
  70. Tirindelli-Danesi D., Teodori L., Mauro F., Modini C., Botti C., Cicconetti F., Stipa S. Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer. 1987 Aug 15;60(4):844–851. doi: 10.1002/1097-0142(19870815)60:4<844::aid-cncr2820600421>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  71. Vassalli J. D., Pepper M. S. Tumour biology. Membrane proteases in focus. Nature. 1994 Jul 7;370(6484):14–15. doi: 10.1038/370014a0. [DOI] [PubMed] [Google Scholar]
  72. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  73. Walker C., Robertson L. J., Myskow M. W., Pendleton N., Dixon G. R. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer. 1994 Aug;70(2):297–303. doi: 10.1038/bjc.1994.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Walker C., Robertson L., Myskow M., Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer. 1995 Jul;72(1):164–169. doi: 10.1038/bjc.1995.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Weiner D. B., Nordberg J., Robinson R., Nowell P. C., Gazdar A., Greene M. I., Williams W. V., Cohen J. A., Kern J. A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990 Jan 15;50(2):421–425. [PubMed] [Google Scholar]
  76. Williams B. O., Remington L., Albert D. M., Mukai S., Bronson R. T., Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 1994 Aug;7(4):480–484. doi: 10.1038/ng0894-480. [DOI] [PubMed] [Google Scholar]
  77. Xu H. J., Quinlan D. C., Davidson A. G., Hu S. X., Summers C. L., Li J., Benedict W. F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994 May 4;86(9):695–699. doi: 10.1093/jnci/86.9.695. [DOI] [PubMed] [Google Scholar]
  78. Yu D., Wang S. S., Dulski K. M., Tsai C. M., Nicolson G. L., Hung M. C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994 Jun 15;54(12):3260–3266. [PubMed] [Google Scholar]
  79. Zimmerman P. V., Hawson G. A., Bint M. H., Parsons P. G. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet. 1987 Sep 5;2(8558):530–533. doi: 10.1016/s0140-6736(87)92923-0. [DOI] [PubMed] [Google Scholar]
  80. ten Velde G. P., Schutte B., Vermeulen A., Volovics A., Reynders M. M., Blijham G. H. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol. 1988 Mar;24(3):455–460. doi: 10.1016/s0277-5379(98)90016-5. [DOI] [PubMed] [Google Scholar]
  81. van Bodegom P. C., Baak J. P., Stroet-van Galen C., Schipper N. W., Wisse-Brekelmans E. C., Vanderschueren R. G., Wagenaar S. S. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long-term follow up. Cancer. 1989 Jan 1;63(1):143–147. doi: 10.1002/1097-0142(19890101)63:1<143::aid-cncr2820630123>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES